Swartz Robin 4
4 · Voyager Therapeutics, Inc. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Voyager Therapeutics (VYGR) COO Robin Swartz Sells 4,569 Shares
What Happened
- Robin Swartz, Chief Operating Officer & Chief Business Officer of Voyager Therapeutics (VYGR), sold 4,569 shares on 2026-02-10 at a weighted-average price of $3.85, for proceeds of about $17,591. This was a sale (not a purchase) and was executed as a sell-to-cover to satisfy tax withholding tied to RSU vesting, not a discretionary trade.
Key Details
- Transaction date: 2026-02-10; weighted-average price reported $3.85.
- Price range: shares sold in multiple transactions at prices from $3.72 to $3.90 (per filing footnote).
- Reason: Sell-to-cover to satisfy tax withholding for RSUs that vested on 2026-02-09 (footnote indicates sales were not discretionary).
- Shares owned after the transaction: not specified in the excerpt provided (see full Form 4 for total beneficial ownership).
- Filing timeliness: Form 4 filed 2026-02-11 (next day), i.e., timely.
Context
- The sale was a routine sell-to-cover associated with restricted stock unit vesting (tax withholding), which is common and does not necessarily indicate an insider's change in view on the company. The filer can provide a breakdown of the number of shares sold at each price in the $3.72–$3.90 range upon request.
Insider Transaction Report
Form 4
Swartz Robin
COO & CBO
Transactions
- Sale
Common Stock
[F1][F2]2026-02-10$3.85/sh−4,569$17,591→ 210,078 total
Footnotes (2)
- [F1]Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The sales do not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.72 to $3.90, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Signature
/s/ Gregory Shiferman, as Attorney-in-Fact for Robin Swartz|2026-02-11